NKT-3964 / NiKang Therap - LARVOL DELTA

NiKang Therapeutics Completes Dosing of the First Cohort in a Phase 1 Study of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 Degrader (Businesswire) - "NiKang Therapeutics Inc...announced today the successful completion of dosing the first cohort of patients in its Phase 1 dose escalation study of NKT3964 as a single agent....The Phase 1 trial (NCT06586957) is an open-label, dose escalation study designed to evaluate safety, tolerability, PK, PD and preliminary anti-tumor activity to determine the recommended dose(s) for expansion of NKT3964 monotherapy in adults with advanced or metastatic solid tumors."

Trial status • Endometrial Cancer • Gastric Cancer • HER2 Negative Breast Cancer • Hormone Receptor Negative Breast Cancer • Ovarian Cancer • Small Cell Lung Cancer • Triple Negative Breast Cancer

Discovery of NKT3964: a first-in-class, highly potent and selective, orally bioavailable CDK2 PROTAC degrader for cancer therapy (EORTC-NCI-AACR 2024) - "In CDK2-dependent cancer cells, NKT3964 potently inhibited Rb phosphorylation and cell proliferation, with 3-to-100-fold higher potency than the clinical CDK2 inhibitor PF-07104091. These results demonstrate that NKT3964 is a potent and selective CDK2 degrader with distinct properties and mechanism of action and has great potential to effectively treat patients with aberrant CDK2/Cyclin E activation in a variety of cancer types. NKT3964 is currently being investigated in a Phase 1 clinical trial in patients with advanced solid tumors."

Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CDK1 • CDK2 • HER-2

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: NiKang Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer

NiKang Therapeutics Presents Discovery of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 PROTAC Degrader for Cancer Therapy, at the EORTC-NCI-AACR Symposium 2024 (Businesswire) - "The company announced today the unveiling of NKT3964 at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics ('Triple Meeting') during a Poster Spotlight Session...NiKang has initiated a phase 1, open-label, dose escalation study of NKT3964 as a single agent."

Clinical • Trial status • Oncology • Solid Tumor

A Study with NKT3964 for Adults with Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: NiKang Therapeutics, Inc.

Metastases • New P1 trial • Breast Cancer • Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer